PS106. Transplantation of Purified CD34+ Cells from Peripheral Blood in Treatment of No-option Critical Limb Ischemia: A Pilot Study

Zhihui Dong,Bin Chen,Zheng Wei,Weiguo Fu,Daqiao Guo,Xin Xu,Xiangman Zhang,Zhenyu Shi,Zhimei Wang,Shanhua Zou,Junhao Jiang,Jue Yang,Ting Zhu,Yuqi Wang
DOI: https://doi.org/10.1016/j.jvs.2011.03.297
IF: 4.86
2011-01-01
Journal of Vascular Surgery
Abstract:To evaluate the safety and efficacy of transplantation of purified peripheral blood CD34+ cells in treatment of no-option critical limb ischemia (NOCLI). From May 2009 to Nov. 2010, 15 NOCLI cases were included, 11 with thromboangitis, 2 atherosclerosis obliterans, and 2 vasculitis, mean age 44±15years. G-CSF was subcutaneously injected for 5 days before apheresis. CD34+ cells were isolated with CliniMACS system, and then intramuscularly injected into calf and foot. Technical success was achieved in all cases. Major amputation was performed in 2 cases postoperatively, and the salvage rate was 87%. The mean number of transplanted cells was (7.84±4.17) ×105/kg. The follow-up was accomplished in all cases, ranging from 1-19 months (mean 8±5months). One month after transplantation, the rest pain was obviously relieved in 11 cases, and the Wong-Baker FACES pain rating scale score significantly decreased from 7±2 to 1±1, P=0.0000. At 6 months, the pain-free walking distance on treadmill measured in 8 eligible cases was significantly improved from 3.0±3.0 min to 17.9±10.6 min (P=0.001); the ankle-brachial index increased from 0.45±0.22 to 0.69±0.13 ( P=0.007); transcutaneous partial oxygen pressure rose from 29±12mmHg to 57±9mmHg (P=0.0002). Of 9 cases with the foot ulcer, it was healed in 6 patients at 4±3months and apparently shrank in 3. No serious complications were observed either perioperatively or during the follow-up. Transplantation of purified peripheral blood CD34+ cells appeared to be safe and effective in treatment of NOCLI, and mid-to-long-term results is pending further investigation.
What problem does this paper attempt to address?